A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer.
The management of hormone-refractory metastatic prostate cancer remains a therapeutic dilemma. We report the results of a phase II trial with deferoxamine administrated at a dose of 50 mg/kg (maximum dose 5 g) administered intravenously over 8 hr daily, repeated for 5 days at 4-week intervals for 2 courses. Fourteen patients with advanced hormone-refractory prostate cancer were treated and 28 courses were delivered. Essentially no toxicity was observed. Using combined clinical and prostate-specific antigen (PSA) criteria. 13 of 14 patients had disease progression. However, 9 of 14 patients had stable measurable or evaluable disease and progressed solely based on PSA criteria. Deferoxamine in this dose and schedule has no activity in hormone-refractory prostate cancer. Further investigation of the effect of deferoxamine on PSA production/expression is warranted.
Dreicer
R
R
Department of Internal Medicine, University of Iowa College of Medicine, University of Iowa Hospitals and Clinics Iowa City, USA.
Kemp
J D
JD
Stegink
L D
LD
Cardillo
T
T
Davis
C S
CS
Forest
P K
PK
See
W A
WA
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000652:urine; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003404:Creatinine / Q000652:urine; D003676:Deferoxamine / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008762:Methylhistidines / Q000652:urine; D008875:Middle Aged; D010388:Pelvis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000652:urine
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D008762:Methylhistidines; D003404:Creatinine; D003676:Deferoxamine; C028118:3-methylhistidine; D006909:Hydroxyproline